Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Kwon

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
Journal for Immunotherapy of Cancer|May 13, 2021
<i>TERT</i> promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitorIvan de Kouchkovsky, Li Zhang, Errol J Philip, et al.
Clinical Genitourinary Cancer|June 14, 2023
Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab VedotinTanya Jindal, Li Zhang, Prianka Deshmukh, et al.
JCO Oncology Practice|December 4, 2025
Evolving Use of Circulating Tumor DNA for HPV+ Oropharyngeal Carcinoma: Consensus Recommendations From the California Head and Neck ConsortiumAllen S Ho, Justin T Moyers, Shirin Attarian, et al.
The Journal of Clinical Investigation|April 5, 2022
Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphomaKatsuyoshi Takata, Lauren C Chong, Daisuke Ennishi, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
Journal for Immunotherapy of Cancer|May 13, 2021
<i>TERT</i> promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitorIvan de Kouchkovsky, Li Zhang, Errol J Philip, et al.
Clinical Genitourinary Cancer|June 14, 2023
Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab VedotinTanya Jindal, Li Zhang, Prianka Deshmukh, et al.
JCO Oncology Practice|December 4, 2025
Evolving Use of Circulating Tumor DNA for HPV+ Oropharyngeal Carcinoma: Consensus Recommendations From the California Head and Neck ConsortiumAllen S Ho, Justin T Moyers, Shirin Attarian, et al.
The Journal of Clinical Investigation|April 5, 2022
Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphomaKatsuyoshi Takata, Lauren C Chong, Daisuke Ennishi, et al.
Pageof 6